Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was founded in 2017 and is headquartered in Waltham, Massachusetts.
IPO Year: 2020
Exchange: NASDAQ
Website: dyne-tx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/24/2024 | $43.00 → $35.00 | Overweight → Neutral | JP Morgan |
| 5/21/2024 | $31.00 → $42.00 | Buy | Chardan Capital Markets |
| 4/30/2024 | $40.00 | Overweight | Morgan Stanley |
| 2/20/2024 | $36.00 | Buy | H.C. Wainwright |
| 2/27/2023 | $16.00 → $27.00 | Outperform → Strong Buy | Raymond James |
| 2/15/2023 | $34.00 | Outperform | Oppenheimer |
| 1/26/2023 | $33.00 | Buy | Guggenheim |
| 7/20/2022 | $17.00 | Buy | Chardan Capital Markets |
| 7/12/2022 | $15.00 | Outperform | Raymond James |
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
424B5 - Dyne Therapeutics, Inc. (0001818794) (Filer)
8-K - Dyne Therapeutics, Inc. (0001818794) (Filer)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
144 - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G - Dyne Therapeutics, Inc. (0001818794) (Subject)
SC 13G/A - Dyne Therapeutics, Inc. (0001818794) (Subject)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
4 - Dyne Therapeutics, Inc. (0001818794) (Issuer)
- IND Application for DYNE-101 for DM1 Cleared by FDA - - New Clinical Data from DYNE-101 ACHIEVE Trial Expected in Early January 2025 - - Enrolling Registrational Cohort of DYNE-251 DELIVER Trial in DMD - WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the third quarter of 2024 and provided a corporate update. "We've made significant progress in our ACHIEVE and DELIVER trials. We are very pleased to have received IND clearance for DYNE-101 a
WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to present at the following upcoming investor conferences: Guggenheim Inaugural Healthcare Innovation Conference, fireside chat on Wednesday, November 13, 2024 at 4:00 p.m. ET in BostonStifel 2024 Healthcare Conference, fireside chat on Tuesday, November 19, 2024 at 3:00 p.m. ET in New YorkPiper Sandler 36th Annual Healthcare Conference, fireside chat on Tuesday, December 3, 2024 at 3:00 p.m. ET in N
WALTHAM, Mass., Sept. 23, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at Chardan's 8th Annual Genetic Medicines Conference being held in New York on Monday, September 30, 2024 at 2:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeut
- Building Team to Prepare for Commercialization as Company Pursues Expedited Approval Pathways for DM1 and DMD Clinical Programs - WALTHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced key leadership appointments to drive its next phase of growth and operational success. Doug Kerr, M.D., Ph.D., MBA, has been appointed chief medical officer (CMO) succeeding Wildon Farwell, M.D., MPH, who is stepping down from his role and will remain at Dyne full-time through the end of 2024 to assist i
- Initiating Registrational Cohorts with Update on Path to Registration by Year-End 2024 -- Virtual Investor Event Today at 8:00 a.m. ET - WALTHAM, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced new clinical data from its ongoing Phase 1/2 DELIVER trial of DYNE-251 in patients with Duchenne muscular dystrophy (DMD) who are amenable to exon 51 skipping demonstrating unprecedented dystrophin expression and functional improvement in multiple cohorts. "We believe these data reinforce the opp
WALTHAM, Mass., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Morgan Stanley 22nd Annual Global Healthcare Conference being held in New York on Thursday, September 5, 2024 at 4:05 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne
- Recent Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrated Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints - - Strengthened Balance Sheet with $374 Million Public Offering Extending Projected Cash Runway At Least Into the Second Half of 2026 - WALTHAM, Mass., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the second quarter of 2024 and recent business highlights. "The second quarter of 2
- Leveraging the FORCE™ Platform, DYNE-302 Achieved Robust and Durable DUX4 Suppression and Functional Benefit in FSHD Preclinical Models - WALTHAM, Mass., June 13, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today highlighted new preclinical data for DYNE-302, its product candidate for facioscapulohumeral muscular dystrophy (FSHD), that demonstrated robust and durable DUX4 suppression and functional benefit. The data were presented during the 31st Annual FSHD Society International Research Congress, being held June 1
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that management is scheduled to participate in a fireside chat at the Jefferies Global Healthcare Conference in New York on Thursday, June 6, 2024 at 3:00 p.m. ET. A live webcast will be available in the Investors & Media section of Dyne's website at https://investors.dyne-tx.com/news-and-events/events-and-presentations and a replay will be accessible for 90 days following the presentation. About Dyne Therapeutics Dyne Therapeutics i
WALTHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the closing of its previously announced underwritten public offering of 12,075,000 shares of its common stock at a public offering price of $31.00 per share, which includes 1,575,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. The gross proceeds to Dyne from the offering were approximately $374.3 million, before deducting underwriting discount
- John Cox, Industry Leader with Global Experience in Rare Disease Commercialization, Joins Dyne as President and CEO - WALTHAM, Mass., March 25, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of John Cox as president, chief executive officer (CEO) and a member of the Board of Directors, effective immediately. He succeeds Joshua Brumm, who has chosen to step down from these roles to pursue a career in healthcare investing. Mr. Brumm will serve as an advisor to Dyne to help ensure a seamles
- Appointment Expands Dyne's Development Team as Company Advances Multiple Programs into Clinical Trials - WALTHAM, Mass., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Francesco Bibbiani, M.D., as senior vice president, head of development. Dr. Bibbiani brings more than two decades of experience across development, including a focus on rare neuromuscular diseases as well as Duchenne muscular dystrophy (DMD). "We are excited to welcome Francesco to Dyne's development
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (NASDAQ:DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Carlo Incerti, M.D., to its Board of Directors. Dr. Incerti has more than three decades of experience in the biopharmaceutical industry, including in rare disease drug development. "We are excited to have Carlo joining the Board as we advance Dyne's programs into the clinic. He brings an extensive track record in global drug development, including from his time at Sanofi Genzyme where he played a leading role in pioneering ther
GLASGOW, Scotland, Sept. 21, 2021 /PRNewswire/ -- Amphista Therapeutics, a leader in next generation targeted protein degradation (TPD) approaches, today announced the appointment of Joshua T. Brumm as its new Independent Chairman, succeeding Satish Jindal. Amphista's CEO Dr Nicola Thompson said, "On behalf of the Amphista team I am thrilled to welcome someone of Josh's calibre to the Board. I look forward to working with Josh as we rapidly develop our pipeline of TPD therapeutics in oncology and beyond and unlock the full therapeutic potential of this exciting new modality. I would also like to thank our outgoing Chairman, Satish Jindal, who has tirelessly given his support as we have succe
Seasoned Clinical Leader Brings Deep Experience in Drug Development, Including Approval of an Oligonucleotide Therapy in Neuromuscular Disease WALTHAM, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Wildon Farwell, M.D., MPH, as chief medical officer. Dr. Farwell brings expertise in clinical development and medical affairs in neuromuscular diseases and oligonucleotide therapies. “Wildon brings tremendous clinical experience and has played a leading role in the development of multipl
Dr. Dugar Brings Over 20 Years of Experience in Medical Affairs, Clinical and Commercial Development, and Real-World Evidence, Including in Rare Muscle Disease WALTHAM, Mass., Feb. 08, 2021 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced the appointment of Ashish Dugar, Ph.D., MBA, as senior vice president, global head of medical affairs. Dr. Dugar brings over 20 years of broad experience across medical affairs, clinical and commercial development, and real-world evidence (RWE) generation. “We are thrilled to welcome Ash to
JP Morgan downgraded Dyne Therapeutics from Overweight to Neutral and set a new price target of $35.00 from $43.00 previously
Chardan Capital Markets reiterated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $42.00 from $31.00 previously
Morgan Stanley initiated coverage of Dyne Therapeutics with a rating of Overweight and set a new price target of $40.00
H.C. Wainwright initiated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $36.00
Raymond James upgraded Dyne Therapeutics from Outperform to Strong Buy and set a new price target of $27.00 from $16.00 previously
Oppenheimer initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $34.00
Guggenheim initiated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $33.00
Chardan Capital Markets initiated coverage of Dyne Therapeutics with a rating of Buy and set a new price target of $17.00
Raymond James initiated coverage of Dyne Therapeutics with a rating of Outperform and set a new price target of $15.00
Jonestrading initiated coverage of Dyne Therapeutics with a rating of Buy
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? QuantumScape Corporation (NYSE:QS) stock jumped 64.34% after the company announced it entered into an agreement with Volkswagen's battery company PowerCo to industrialize solid-state batteries. Lantheus Holdings, Inc. (NASDAQ:LNTH) shares rocketed 55.93% following a CMS proposal to improve payment for Specialized Diagnostic Radiopharmaceuticals. Sunrun Inc. (NASDAQ:RUN) shares increased 37.59%. as shares of companies within the broader industrial sector gained following recent CPI data. Kymera Therapeutics, Inc. (NASDAQ:KYMR) shares rose 37.38% after the company announced its intentio
JP Morgan analyst Tessa Romero maintains Dyne Therapeutics (NASDAQ:DYN) with a Overweight and raises the price target from $39 to $43.
U.S. stocks were higher, with the Nasdaq Composite gaining over 250 points on Wednesday. Shares of Casey’s General Stores, Inc. (NASDAQ:CASY) rose sharply during Wednesday's session after the company reported better-than-expected quarterly financial results. Also, the company increased its quarterly dividend. Sales of $3.60 billion exceeded the street view of $3.48 billion. EPS of $2.34 beat the consensus of $1.72, according to data from Benzinga Pro. Casey’s General Stores shares jumped 16.5% to $380.41 on Wednesday. Here are some other big stocks recording gains in today’s session. Avidity Biosciences, Inc. (NASDAQ:RNA) surged 27% to $36.56 after the company announced initi
A cooler-than-expected U.S. inflation report fueled a rally on Wall Street, ahead of the highly anticipated Federal Open Market Committee (FOMC) meeting at 2:00 p.m. Wednesday. What happened: Inflation slowed to 3.3% annually in May, below both the expected and previous rate of 3.4%. On a monthly basis, the Consumer Price Index (CPI) remained flat, below the anticipated 0.1% increase and a significant drop from April’s 0.3% rise. Additionally, the core measure of inflation, which excludes energy and food, weakened more than predicted. Annually, core inflation slowed from 3.6% to 3.4%, falling short of the 3.5% expectation. Why it matters: Lower-than-expected inflation data is bolste
U.S. stock futures were lower this morning, with the Dow futures falling around 50 points on Wednesday. Shares of Modine Manufacturing Company (NYSE:MOD) shares fell sharply in today’s pre-market trading following mixed fourth-quarter results. Modine Manufacturing posted adjusted earnings of 77 cents per share, versus market estimates of 76 cents per share. The company's quarterly sales came in at $603.50 million compared to expectations of $605.36 million, according to data from Benzinga Pro. Modine Manufacturing shares tumbled 8.8% to $92.50 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. LifeStance Health Group, Inc.
The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offering expenses payable by Dyne, are expected to be $325.5 million. All shares in the offering are being sold by Dyne. The offering is expected to close on or about May 24, 2024
Chardan Capital analyst Keay Nakae maintains Dyne Therapeutics (NASDAQ:DYN) with a Buy and raises the price target from $31 to $42.
Dyne Therapeutics, Inc. (NASDAQ:DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares in the proposed offering are to be sold by Dyne.